FDA
-
-
-
-
-
-
-
Arbutus Biopharma (ABUS) Announces 2024 Corporate Objectives and Provides Financial Update
-
-
-
-
-
-
-
Arbutus Reports Second Quarter 2023 Financial Results and Corporate Update
-
-
-
-
-
-
-
Arbutus Reports Third Quarter 2021 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Pre-Open Stock Movers 05/11: (MYOK) (AMC) (AVYA) Higher; (VUZI) (UA) (PENN) Lower (more...)
-
-
-
-
-
-
-
Arbutus Reports First Quarter 2019 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Arbutus’ LNP Licensee Alnylam Announces FDA Approval of ONPATTRO™ (patisiran), for the Treatment of ATTR Amyloidosis
-
-
-
-
-
-
-
Arbutus Announces Corporate Update and Year-End 2017 Financial Results
-
323,579 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

